

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using single molecule measurement digital platform, Simoa. Quanterix, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, has selected ABL, the first CRO in Europe with the ability to develop new assays and validate methods for research or clinical testing to detect femtomolar levels of analytes in preclinical or clinical samples.

“ Quanterix is very pleased that our Simoa technology has now been adopted by one of Europe’s leading CROs, giving our customers in the pharmaceutical industry an incredibly experienced and competent partner for their assay needs when Simoa’s exquisite sensitivity, multiplexing capability, and automation are needed, ” said Kevin Hrusovsky, Chairman and CEO. “We believe PPS can significantly accelerate the ground-breaking work our customers are already conducting in Europe with Simoa.”

The main mission of PPS is to adapt to the needs of its customers by offering the optimal platform and methods that will best help understand science. Using Simoa’s single molecule detection capabilities, PPS will now be able to provide their customers with fully automated and robust methods, ensuring consistent results. The Simoa technology becomes an integral part of innovative solutions for biomarker discovery and testing in its laboratory, in Lyon, France.

“It seems natural that PPS offers Simoa technology. It indeed complements our existing offering of alternative and traditional technologies to measure biomarkers, in which Simoa will help our sponsors to robustly detect low concentrations of markers by using a smaller volume of samples,” said Michel Popielarz, European Sales Manager. “Capitalizing on our expertise in developing tests, we are confident we can best meet the expectations of our clients, whether for research projects, clinical trials, or within early biomarker qualification processes and companion diagnostic projects.”

About Platine Pharma Services SAS

PPS is located in Lyon (France) which offers services for research and development projects as well as preclinical and clinical studies. PPS is specialized in immunological approaches that includes soluble biomarkers quantification as well as phenotypic and functional cell characterization by using state-of-the-art technology platforms. For more information on PPS and our services, please visit our website at <http://www.platine-lab.com>

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.querix.com.

About ABL, Inc.

ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has immunological and molecular laboratories in Rockville MD, USA and in Lyon, France, to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to

developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at <http://www.ablinc.com/> or email us at info@ablinc.com

Platine Pharma Services Contact:

Michel Popielarz
+33 4 3770 8700
info@platine-lab.com

ABL Contact:

Andrew A. Arrage
301-881-5600
info@ablinc.com

Nikki Festa & Caitlyn Keating
PAN Communications
617-502-4300
quanterix@pancomm.com